Tuberculosis and Respiratory Diseases
- Volume 49 Issue 4
- /
- Pages.421-431
- /
- 2000
- /
- 1738-3536(pISSN)
- /
- 2005-6184(eISSN)
The Length of Postoperative Antituberculous Therapy in Patients with Pulmonary Tuberculosis
폐결핵 환자의 폐절제술 후 항결핵제 투여기간
- Kwon, Eun-Su (National Masan Tuberculosis Hospital) ;
- Song, Jin-Ho (National Masan Tuberculosis Hospital) ;
- Song, Sun-Dae (National Masan Tuberculosis Hospital)
- Published : 2000.10.30
Abstract
Background : The length of postoperative drug therapy remains controversial in pulmonary tuberculosis. We analyzed our experiences to determine the postoperative duration of chemotherapy after resection. Method : A retrospective review was performed in 66 of 95 patients that underwent pulmonary resection for pulmonary tuberculosis between January 1993 and December 1998. We compared the relapse rates according to the length of postoperative chemotherapy in each group, classified by the results of sputum AFB culture before the surgery, the number of resistant drugs, the number of prior treatment and the division of anti-TB drugs used postoperatively. Results : Fifty three of 66(80.3%) were men and 13(19.7%) were women with a median age of 33.5 years(range, 16 to 63). The mean lengths of the pre- and post-operative chemotherapies were 4.9 months, and 12.9 months respectively. Five of 66 patients (7.6%) relapsed during the mean period of follow up (39.7 months). In the group less than three times of the prior treatment, there were two relapses (20%) in Ed-the highlight above-rephrase 10 patients that were medicated for 6 months or less, and one relapse in 43 patients (2.3%) that took medicine for more than 6 months (p=0.03). In the group using second-line drugs postoperatively, there was one relapse (25%) in four patients that were medicated for 12 months or less. No patient in a total of 17 that received medicine for more than 12 months relapsed (p=0.03). Conclusion : We recommend that patients with the prior treatment less than three times should be treated for more than 6 months after resection and patients using the second-line drugs postoperatively should be medicated for more than 12 months.
연구배경 : 오늘날 폐결핵의 치료에 있어 폐절제술이 폐결핵 치료의 보조적 역할을 하게 됨으로써 수술뿐 만 아니라 술전 및 술후 투약의 중요성이 강조되었다. 그러나, 폐결핵의 폐절제술 후 투약기간에 대해서는 관련 논문의 저자에 따라, 참고 문헌에 따라 다양하고 차이가 있다. 이에 본 연구는 폐결핵환자에서 폐절제술 후 투약 기간에 따른 재발율을 후향적으로 비교 분석함으로써 술후에 적절한 투약기간을 찾고자 하였다. 방법 : 국립마산결핵병원에서 1993년 1월부터 1998년 12월까지 폐절제술이 시행된 95예 중 수술 후 항결핵제로 치료종결하고 추적관찰이 가능했던 예, 술후 투약 중 치료실패 하였으나 약제 변경 등을 통하여 무사히 치료종결하고 추적관찰이 가능하였던 예, 술후 투약을 조기에 종결하고 추적관찰 가능하였으며, 재발 또는 악화된 예를 포함하여 총 66예를 대상으로 진료기록을 중심으로 조사하였다. 치료종결 후 술후 투약기간을 6, 9, 12, 18, 24개월 단위별, 기준별로 분류하여 각 군의 재발율을